Ceftriaxone (Standard)

Ceftriaxone (Standard) is the analytical standard of Ceftriaxone. This product is intended for research and analytical applications. Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[73384-59-5]

Product Name Alternative

Ro 13-9904 (free acid) (Standard)

UNSPSC

12352005

Target

Antibiotic; Aurora Kinase; Bacterial; GSK-3; Reference Standards

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics; Others; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cancer; Infection; Inflammation/Immunology

Purity

97.08

Smiles

O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O

Molecular Formula

C18H18N8O7S3

Molecular Weight

554.58

References & Citations

[1]Nahata MC, et al. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm. 1985 Dec;19 (12) :900-6.|[2] Nassar H, et al. Molecular docking, molecular dynamics simulations and in vitro screening reveal cefixime and ceftriaxone as GSK3β covalent inhibitors. RSC Adv. 2023 Apr 11;13 (17) :11278-11290.|[3]Zhang Y, et al. Ceftriaxone Protects Astrocytes from MPP (+) via Suppression of NF-κB/JNK/c-Jun Signaling. Mol Neurobiol. 2015 Aug;52 (1) :78-92.|[4]Li X, et al. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis. 2012 Dec;33 (12) :2548-57.|[5]Hakimizadeh E, et al. Ceftriaxone improves hepatorenal damages in mice subjected to D-galactose-induced aging. Life Sci. 2020 Oct 1;258:118119.|[6]Uyanikgil Y, et al. Positive effects of ceftriaxone on pentylenetetrazol-induced convulsion model in rats. Int J Neurosci. 2016;126 (1) :70-5.|[7]Gunduz O, et al. Anti-allodynic and anti-hyperalgesic effects of ceftriaxone in streptozocin-induced diabetic rats. Neurosci Lett. 2011 Mar 10;491 (1) :23-5.